Anticancer agent 47 (compound 4j) exhibits potent anticancer properties, demonstrating antiproliferative activities, inducing apoptosis, and causing cell cycle arrest at the G0/G1 phase. Moreover, Anticancer agent 47 has shown significant in vivo antitumor activities [1].

Anticancer agent 47 (compound 4j) exhibits antiproliferative activity with IC50 values of 1.6, 0.72, and 7.07 μM for HepG2, A549, and H596 cells, respectively [1]. At concentrations of 0.8, 1.6, and 3.2 μM for 24 h, it induces apoptosis and cell cycle arrest at the G0/G1 phase [1]. At 5 μM for 5 h, it significantly increases ROS production [1]. Apoptosis analysis for HepG2 and H596 cells at 0.8, 1.6, and 3.2 μM for 24 h resulted in apoptotic cell rates of 14.23%, 20.47%, and 27.66%, respectively. Cell cycle analysis for HepG2 cells revealed 48.54%, 49.60%, and 53.00% of cells at G0/G1 phase at 0.6, 1.2, and 2.4 μM, respectively [1].

Anticancer agent 47, administered intravenously at a dosage of 20 mg/kg every other day for 19 days, demonstrates significant antitumor activities in BALB/c nude mice bearing HepG2 xenografts. This regimen effectively inhibited tumor growth, achieving a tumor inhibition rate of 58.7%.